Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical Conferences [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation for three major clinical conferences this quarter. These events are pivotal to the company's expansion, providing U.S. clinicians dir ...

Core Insights - Baird Medical has launched its Microwave Ablation technology at Bakersfield Memorial Hospital, marking a significant step in its U.S. market penetration and commitment to enhancing patient access to advanced care [1][2] - The inaugural procedure for benign thyroid tumors was successfully performed, showcasing the technology's efficiency and safety in a high-volume hospital setting [1] - This launch aligns with Baird Medical's strategic commercial roadmap, aiming to drive the adoption of interventional therapies and improve patient care standards [2] Company Overview - Baird Medical Investment Holdings Ltd. specializes in minimally invasive diagnostics and treatment, focusing on surgical robotic systems and innovative surgical instruments [2] - The company is FDA 510(k)-certified and has its solutions utilized in over 30 prestigious hospitals across the U.S., including Mayo Clinic and UCSF Medical Center [2] - Baird Medical is a market leader in China for thyroid microwave ablation devices and is expanding its commercial presence in over 20 countries worldwide [2]

The event featured a combination of expert-led didactic lectures and live case observations, providing participating physicians from across Asia with critical insights into clinical applications and techniques. By focusing on both theoretical knowledge and practical application, the Masterclass reinforced the importance of precision in clinical practice and facilitated the exchange of advanced methodology among regional specialists. This initiative highlights Baird Medical's enduring commitment to physicia ...

Core Insights - Baird Medical Investment Holdings Ltd. is a leader in minimally invasive Microwave Ablation (MWA) technology and successfully participated in the 44th Annual J.P. Morgan Healthcare Conference [1] Group 1: Company Overview - Baird Medical specializes in minimally invasive diagnostics and treatment, focusing on surgical robotic systems and innovative surgical instruments [4] - The company aims to enhance patient outcomes through precision technology and advanced diagnostic solutions, and has established partnerships with leading academic institutions [4] - Baird Medical is FDA 510(k)-certified and its solutions are utilized in over 30 prestigious hospitals and clinics across the U.S., including Mayo Clinic and UCSF Medical Center [4] - The company is also a market leader in China for thyroid microwave ablation devices and is expanding its commercial presence in over 20 countries worldwide [4] Group 2: Strategic Focus - During the J.P. Morgan Healthcare Conference, Baird Medical's leadership discussed the company's 2026 strategic priorities, emphasizing the acceleration of its U.S. commercial footprint and the adoption of thyroid ablation technologies [2] - The U.S. CEO, Mark Saxton, highlighted the market's interest in Baird Medical's differentiated MWA platform and the company's commitment to driving clinical excellence and sustainable growth [3] - Following the conference, Baird Medical remains focused on executing its operational roadmap to enhance shareholder value and expand patient access to its minimally invasive solutions [3]

Core Insights - The company has successfully launched its product in Pakistan at the Armed Forces Institute of Radiology & Imaging, guided by Dr. Raza Raheem, a key figure in interventional radiology [1] - The registration approval in Vietnam signifies a major expansion of Baird Medical's presence in the Southeast Asian market, highlighting the company's commitment to global commercialization [2][3] Company Overview - Baird Medical specializes in minimally invasive diagnostics and treatment, focusing on surgical robotic systems and innovative surgical instruments [3] - The company aims to enhance patient outcomes through precision technology and advanced diagnostic solutions, and plans to collaborate with leading academic institutions [3] - Baird Medical is FDA 510(k)-certified and its solutions are utilized in over 30 prestigious hospitals in the U.S., including Mayo Clinic and UCSF Medical Center [3] - The company is a market leader in China for thyroid microwave ablation devices and is expanding its commercial presence in over 20 countries [3]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. 333-283249 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Baird Medical Investment Holdings Limited (Exact name of Registrant as specified in its charter) (I.R.S. Employer Identification Number) The Cayman Islands 3711 Not Applicable (State or other jurisdiction of incorporation or organization ...

Page | Baird Medical Investment Holdings Limited | | | --- | --- | | Unaudited Interim Condensed Consolidated Balance Sheets as of December 31, 2024 and June 30, 2025 | F-2 | | Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Income/Loss for the | | | six months ended June 30, 2024 and 2025 | F-3 | | Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' equity for the six months | | | ended June 30, 2024 and 2025 | F-4 | | Unaudited Interim Conden ...

Core Insights - Baird Medical Investment Holdings Ltd. has appointed Mark Saxton as the new CEO of its U.S. subsidiary, aiming to enhance its market presence in the U.S. [1] - Saxton brings over 25 years of experience in the medical device industry, particularly in intravascular RF ablation technologies, and has a history of driving significant revenue growth and successful exits for medtech companies [1] - The company is focused on advancing its Microwave Ablation technology, which offers advantages in minimally invasive care, and aims to expand access for patients while creating shareholder value [1] Company Overview - Baird Medical specializes in minimally invasive diagnostics and treatment, with a commitment to research and development of surgical robotic systems and innovative surgical instruments [1] - The company is FDA 510(k)-certified and its solutions are utilized in over 30 prestigious hospitals and clinics in the U.S., including Mayo Clinic and UCSF Medical Center [1] - Baird Medical is a market leader in China for thyroid microwave ablation devices and is expanding its commercial presence in over 20 countries worldwide [1]

Core Insights - Baird Medical Investment Holdings Ltd. has officially launched its Microwave Ablation (MWA) technology in the Egyptian market with a successful procedure at Ain Shams Specialized Hospital [1][2][3] Company Overview - Baird Medical specializes in minimally invasive diagnostics and treatment, focusing on surgical robotic systems and innovative surgical instruments [3] - The company is FDA 510(k)-certified and has a presence in over 30 prestigious hospitals in the United States, including Johns Hopkins Hospital and Columbia University Medical Center [3] - Baird Medical is a market leader in China for thyroid microwave ablation devices and is expanding its commercial presence in over 20 countries worldwide [3] Recent Developments - The first procedure in Egypt involved a bone ablation for a 30-year-old male patient, successfully achieving full ablation and significant pain relief [2] - This procedure demonstrates the versatility of Baird's MWA system, extending its application from soft tissue to musculoskeletal treatments [2][3] - The company aims to enhance global access to advanced, non-surgical solutions through strategic partnerships with leading academic institutions [3]

Core Insights - Baird Medical Investment Holdings Ltd. has announced the clinical adoption of its Microwave Ablation (MWA) system at Elk Medical, a private endocrinology practice in Brooklyn, New York, marking a significant step in expanding access to minimally invasive thyroid treatments [1][3] Company Overview - Baird Medical specializes in minimally invasive diagnostics and treatment, focusing on surgical robotic systems and innovative surgical instruments, with a mission to enhance patient outcomes through precision technology [4] - The company is FDA 510(k)-certified and its solutions are utilized in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital and Columbia University Medical Center [4] - Baird Medical is a market leader in China for thyroid microwave ablation devices and consumables, and is expanding its commercial presence in over 20 countries worldwide [4] Clinical Adoption and Economic Viability - Dr. Kazeem, an experienced endocrinologist, has performed nine MWA procedures recently, focusing on large thyroid nodules as a non-surgical treatment option [2] - The initial MWA procedures have been successfully reimbursed by Medicare, indicating potential for broader patient access and economic viability of MWA therapy [3]